Expanding the genetic landscape of endometriosis: Integrative -omics analyses uncover key pathways from a multi-ancestry study of over 900,000 women

6 Authors and Affiliations

Lindsay A Guare¹, Jagyashila Das¹, Lannawill Caruth¹, Ananya Rajagopalan², Alexis T.
Akerele³, Ben M Brumpton⁴, Tzu-Ting Chen⁵, Leah Kottyan⁶, Yen-Feng Lin⁵, Elisa Moreno⁴,
Ashley J Mulford⁷, Vita Rovite⁸, Alan R Sanders⁷, Marija Simona Dombrovska⁸, Noemie Elhadad⁹,
Andrew Hill¹⁰, Gail Jarvik¹¹, James Jaworski¹², Yuan Luo¹³, Shinichi Namba¹⁴, Yukinori Okada¹⁴,
Yue Shi¹⁵, Yuya Shirai¹⁶, Jonathan Shortt¹⁰, Wei-Qi Wei¹⁷, Chunhua Weng⁹, Yuji Yamamoto¹⁶,
Sinead Chapman¹⁵, Wei Zhou¹⁵, Digna R. Velez Edwards¹⁸, Shefali Setia-Verma¹

13 Corresponding Author: Shefali Setia-Verma

¹Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, 14 United States, ²Genomics and Computational Biology, University of Pennsylvania, Philadelphia, 15 PA, United States, ³Division of Quantitaive Science, Department of Obstetrics and Gynecology, 16 17 Department of Microbiology, Immunology, and Physiology, Vanderbilt University Medical Center, and Meharry Medical College, Nashville, TN, United States, ⁴HUNT Center for Molecular 18 and Clinical Epidemiology, Norwegian University of Science and Technology, Trondheim, 19 Norway, ⁵Center for Neuropsychiatric Research, National Health Research Institutes, Maoli 20 County. Taiwan, ⁶Cincinnati Children's Hospital Medical Center, Cincinatti, OH, United States, 21

⁷Endeavor Health, Evanston, IL, United States, ⁸Latviant Biomedical Research and Study Centre, 22 Riga, Riga, Latvia, ⁹Biomedical Informatics, Columbia University, New York City, NY, United 23 States, ¹⁰Colorado for Precision Medicine, Aurora, CO, United States, ¹¹Division of Medical 24 Genetics, University of Washington, Seattle, WA, United States, ¹²Division of Epidemiology, 25 26 Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, United 27 States, ¹³Feinberg School of Medicine, Northwestern University, Evanston, IL, United States, ¹⁴Genome Informatics. The University of Tokyo, Tokyo, Japan, ¹⁵Broad Institute, Cambridge, 28 MA, United States, ¹⁶Statistical Genetics, Osaka University, Suita, Osaka, Japan, ¹⁷Biomedical 29 Informatics, Vanderbilt University, Nashville, TN, United States, ¹⁸Division of Quantitative 30 Science, Department of Obstetrics and Gynecology, Vanderbilt University Medical Center, 31 32 Nashville, Tennessee, United States

33 Abstract

34 We report the findings of a genome-wide association study (GWAS) meta-analysis of endometriosis consisting of a large portion (31%) of non-European samples across 14 biobanks 35 36 worldwide as part of the Global Biobank Meta-Analysis Initiative (GBMI). We identified 45 37 significant loci using a wide phenotype definition, seven of which are previously unreported and detected first genome-wide significant locus (POLR2M) among only African-ancestry. Our 38 39 narrow phenotypes and surgically confirmed case definitions for endometriosis analyses 40 replicated the known loci near CDC42, SKAP1, and GREB1. Through this large ancestry stratified analyses, we document heritability estimates in range of 10-12% for all ancestral groups. Thirty-41 eight loci had at least one variant in the credible set after fine-mapping. An imputed 42

43 transcriptome-wide association study (TWAS) identified 11 associated genes (two previously 44 unreported), while the proteome-wide association study (PWAS) suggests significant 45 association of R-spondin 3 (RSPO3) with wide endometriosis, which plays a crucial role in 46 modulating the Wnt signaling pathway. Our diverse, comprehensive GWAS, coupled with 47 integrative -omics analysis, identifies critical roles of immunopathogenesis, Wnt signaling, and 48 balance between proliferation, differentiation, and migration of endometrial cells as hallmarks 49 for endometriosis. These interconnected pathways and risk factors underscore a complex, multi-faceted etiology of endometriosis, suggesting multiple targets for precise and effective 50 therapeutic interventions. 51

52 Introduction

Endometriosis, a debilitating condition characterized by the growth of endometrial-like tissues outside of the uterus affects approximately 10% of women of reproductive age worldwide^{1,2}. The precise mechanisms of these lesions are presently unknown. Endometriosis is incurable, leaving patients to manage severe pain³ and cope with fertility challenges⁴. Despite its prevalence and impact, the etiology of endometriosis remains poorly understood, hampering efforts to develop effective diagnostic tools and targeted treatments.

59 Genome-wide association studies (GWASs) have been an important tool for implicating 60 candidate genes and pathways linked with endometriosis. GWASs for endometriosis have 61 uncovered over 40 loci associated with endometriosis risk. However, like most GWASs 62 historically, the previous endometriosis studies have primarily included European populations 63 with some East-Asian datasets as well⁵. Consequently, they have explained about 7% of

64 phenotypic variance with common variants^{6,7} and have fallen short in elucidating the full
65 spectrum of its pathophysiology.

The advent of large-scale biobanks has revolutionized genetic research, offering unique 66 67 opportunities to conduct well-powered studies across diverse populations. As more diverse genomic datasets are developed, like the Penn Medicine Biobank (PMBB)⁸, the All of Us 68 Research Program (AOU)⁹, and the Million Veterans Program (MVP)¹⁰, that diversity can 69 increase statistical power and enhance the discovery of trait loci¹¹. A worldwide consortium of 70 genomic researchers, the global biobank meta-analysis initiative (GBMI), was established to 71 facilitate collaboration in GWAS studies on unprecedented scales. In this study, we have 72 collaborated with 12 biobanks across several countries^{9,12-22}. These resources not only enhance 73 74 statistical power to detect novel associations but also provide rich phenotypic data, enabling 75 more refined analyses. Moreover, the inclusion of diverse ancestries in genetic studies is crucial for improving the generalizability of findings and addressing health disparities. This is 76 77 particularly pertinent for endometriosis, where significant variations in prevalence and clinical presentation have been observed across different ethnic groups²³. 78

Beyond GWAS, there are many methods which can be employed *in silico* to investigate other elements of the central dogma, providing further validation of GWAS loci and discovery of additional disease-associated genes. Recent advances in multi-omics technologies have further expanded our ability to translate genetic associations into biological insights. Integration of GWAS results with transcriptomic, proteomic, and single-cell data using methods such allows for a more comprehensive understanding of disease mechanisms, potentially identifying novel therapeutic targets and biomarkers. Then, these multi-omic layers of association can be

medRxiv preprint doi: https://doi.org/10.1101/2024.11.26.24316723; this version posted November 29, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

integrated using tools such as Mergeomics²⁴, which also identifies gene sets enriched for association with the disease of interest. For endometriosis, where the interplay between genetic predisposition and complex tissue-specific processes is central to its pathogenesis, such integrative approaches are especially valuable. Given these considerations, there is a critical need for a large-scale, ancestrally diverse GWAS of endometriosis that incorporates rigorous phenotyping and leverages multi-omics data to provide a more complete picture of the disease's genetic landscape and underlying biology.

Here, we present the results of large-scale GWAS meta-analyses that significantly 93 94 advances our understanding of endometriosis pathophysiology. Our study encompasses a 95 diverse cohort from 14 biobanks worldwide, with over 30% non-European participants, 96 enhancing the generalizability of our findings. We employed a comprehensive phenotyping 97 approach, including not only a wide spectrum of endometriosis presentations but also surgically 98 confirmed and procedure-validated (surgery or imaging) phenotypes. This rigorous phenotyping 99 strategy allows for a more nuanced exploration of the genetic architecture underlying various manifestations of endometriosis. Through integrative multi-omics analyses, incorporating 100 101 transcriptomic, proteomic, and single-cell data from endometrial tissues, we have explored five 102 major hallmarks of endometriosis pathogenesis. These findings provide unprecedented insights 103 into the molecular mechanisms driving this complex disorder, paving the way for improved 104 diagnostics and targeted therapeutic interventions.

105 **Results**

106	EHR-Based Phenotyping of Endometriosis in Genetically Diverse Datasets
107	We considered six phenotype definitions for our GWASs: wide endometriosis (W), wide
108	endometriosis excluding cases and controls with adenomyosis (Wex), procedure-confirmed
109	narrow endometriosis versus all controls (PCN.v1) and versus procedure-confirmed controls
110	(PCN.v2), and surgically-confirmed narrow endometriosis versus all controls (SCN.v1) and
111	versus surgically-confirmed controls (SCN.v2). The largest phenotype, W, comprised 928,413
112	women, including 44,125 cases. We leveraged publicly-available FinnGen ²⁵ and MVP ¹⁰ summary
113	statistics to increase the sample size. The Wex phenotype, for which several biobanks were
114	omitted, had a total sample size of $434,444$ ($N_{cases} = 8,122$). Sample sizes for the PCN and SCN
115	phenotypes were smaller (Table 1), with summary statistics included from only eight of the 12
116	contributing GBMI biobanks (Supplementary Table 1).

117Table 1: All GWAS meta-analysis sample sizes. All six phenotypes had a multi-ancestry meta-analysis as well as118single-ancestry meta-analyses for AFR, AMR, EAS, and EUR. There were not enough EAS studies to conduct meta-119analyses for the surgically confirmed narrow (SCN) phenotypes.


	<u> </u>		````	, , , , , , , , , , , , , , , , , , ,
Phenotype	Ancestry	Ν	Cases	Prevalence
	AFR	74,976	2,772	3.70%
	AMR	38,837	1,262	3.25%
W	CSA	5,222	208	3.98%
vv	EAS	165,464	7,814	4.72%
	EUR	643,914	32,069	4.98%
	META	928,413	44,125	4.75%
	AFR	56,314	862	1.53%
	AMR	38,195	620	1.62%
Mari	CSA	5,066	62	1.22%
Wex	EAS	80,375	1,531	1.90%
	EUR	254,494	5,047	1.98%
	META	434,444	8,122	1.87%
	AFR	51,050	823	1.61%
PCN.v1	AMR	36,719	599	1.63%
	EAS	78,999	155	0.20%

	EUR	209,207	3,207	1.53%
	META	375,975	4,784	1.27%
	AFR	9,874	823	8.34%
	AMR	7,113	599	8.42%
PCN.v2	EAS	1,539	155	10.07%
	EUR	35,722	3,207	8.98%
	META	54,248	4,784	8.82%
	AFR	50,592	365	0.72%
SCN.v1	AMR	36,465	345	0.95%
SCIV.VI	EUR	208,136	2,137	1.03%
	META	295,193	2,847	0.96%
	AFR	1,436	365	25.42%
SCN.v2	AMR	1,957	345	17.63%
SCIV.VZ	EUR	12,926	2,137	16.53%
	META	16,319	2,847	17.45%

120 Multi-Ancestry GWAS Meta-Analysis Results

All 4,983 genome-wide significant variants ($P < 5 \times 10^{-8}$) from all meta-analyses are listed in 121 Supplementary Table 2. The primary meta-analysis performed (multi-ancestry, wide phenotype) 122 123 yielded 96 regions. From there, physically overlapping clumps were merged, resulting in 42 loci 124 significantly associated with endometriosis. Besides those 42, there were two EUR-specific loci (LINC01317 and LINC02456) and one AFR-specific locus (POLR2M), totaling 45 loci annotated in 125 Figure 1a (Supplementary Table 3). All EAS loci overlapped with loci from the multi-ancestry 126 meta-analyses, and the AMR W GWAS did not yield any genome-wide significant loci. Of the 45 127 unique W loci. 24 of their lead SNPs were in LD ($R^2 > 0.25$) with the lead SNPs reported in 128 129 Rahmioglu et al, 2023, and an additional 14 were found within 50 Mb of the 2023 GWAS lead 130 SNPs. The seven remaining loci were unreported in the 2023 GWAS: RUVBL1 (rs4058156. P = 3.51E-10), 3q28 (rs9870207, P = 4.17E-09), 5p13.1 (rs55920409, P = 2.66E-08), VAPA 131 (rs79380316, P = 3.56E-08), DTD1 (rs6112068, P = 8.72E-10), ZHX3 (rs17265513, P = 5.58E-09), 132 MIRLET7BHG (rs873492, P = 4.80E-08). The observed SNP heritability, computed with LDSC, was 133 significantly greater than zero (P < 0.05) in the multi-ancestry meta-analysis (h^2_{lia} = 0.070) as 134 well as the AFR ($h^2_{lia} = 0.129$), EAS ($h^2_{lia} = 0.108$), and EUR ($h^2_{lia} = 0.108$) single-ancestry meta-135 136 analyses (Figure 1b).

137



138 139

Figure 1: main meta-analysis results. Top left: overlayed Manhattan plots for the five W GWASs (multi-ancestry + four single-ancestries). Significant loci are highlighted, with black text representing the previously unreported hits. Bottom left: Overlayed Manhattan plots for the five multi-ancestry GWASs for the other phenotypes. All loci are previously reported. Top right: LDSC heritability estimates for the W GWASs; AMR is excluded because the heritability estimate was not significant. Bottom right: volcano plot highlighting variants with an absolute log-odds effect size > 0.1, colored by ancestry group.

145 Precise Phenotype Analyses Replicate Known Loci

146 For the other phenotype meta-analyses, we identified seven significant loci: two for EUR and 147 multi-ancestry (SCN.v2 and SCN.v1), one for AFR and multi-ancestry (SCN.v1), three just in 148 multi-ancestry (two Wex and one SCN.v1), and one just in AMR (PCN.v1). Both loci associated 149 with Wex in the multi-ancestry analysis replicate known signals. CDC42 (rs56319427, P = 4.91E-11) is in LD (R2 = 0.91) with the previous CDC42 locus, and RMND1 (rs9322319, P = 2.86E-08) is 150 151 near the previous SYNE1 locus. The five loci identified with the narrow phenotypes are within 152 50Mb of known signals, so they are not considered previously unreported. The surgically-153 confirmed cases vs all controls phenotype (SCN.v1) yielded two loci: 2p13.3 (rs116763937, P = 4.07E-08), also significant in AFR, and CD163 (rs118078722, P = 1.39E-08), also significant in 154 EUR. When comparing surgically-confirmed cases with only surgically-confirmed controls 155

156 (SCN.v2), we identified two loci: KCNF1 (rs115117372, P = 1.97E-08) and 12q24.32 (rs12581759, 157 P = 2.64E-08), with KCNF1 also significant in the EUR meta-analysis. The final locus, OTUD7A 158 (rs17762839, P = 1.72E-08), was associated with the PCN.v1 phenotype in the AMR meta-159 analysis. These loci are displayed in Figure 1c.

160 Fine-Mapping to Detect Causal Variants at GWAS Loci

161 To elucidate shared and population-specific putative causal variants, we conducted statistical fine-mapping on all hits from multi-population meta-analyses, totaling 48 loci in five (PCN.v2 162 163 had no significant hits) studies (See Methods). Of those 48 loci, 38 had at least one variant with posterior probability of being causal (PIP) greater than 0.5, totaling 132 causal variants 164 165 (Supplementary Table 4). The cross-ancestry fine-mapping analyses computed PIPs for each 166 variant across all combinations of ancestry groups included in the overall study. We identified credible sets (CS) for the 38 distinct loci associated with endometriosis as reported in Table 2. 167

- 168 169 170

Table 2: credible sets of multi-ancestry GWAS loci. 34 are for the W phenotype, 2 are for Wex, and 2 are for SCN.v2 (SCN cases versus surgically-confirmed controls). An "X" in the AFR-EUR columns denote whether that ancestry group was used for detecting any SNPs in the credible set (PIP > 0.5). Locus names match the GWAS.

Phenotyp					AM			
е	Locus	Locus P	# CS	AFR	R	EAS	EUR	Credible Set
W	WNT4	1.12E-37	3			X	Х	rs2473331, rs61768001, rs16826658
W	MIR4418	1.85E-09	3	Х		X	Х	rs1934478, rs10917216, rs12097230
								rs12030576, rs11102915, rs6656381,
W	NGF-AS1	1.11E-08	4			Х	Х	rs12075799
W	DNM3	2.38E-08	2		Х	Х	Х	rs479960, rs569179
W	GREB1	2.45E-25	2		Х	X	Х	rs10929759, rs10165819
								rs12614817, rs6716567, rs2134811,
W	FSHR	8.59E-10	6	Х	Х	Х	Х	rs13032266, rs4420736, rs6722885
W	2p14	2.23E-15	2			Х	Х	rs2683680, rs2860517
								rs13018792, rs67436597,
W	DIRC3	6.11E-09	3			Х	Х	rs72613753
W	EEFSEC	1.00E-09	2		Х		Х	rs2955102, rs2811529
								rs9870207, rs6778588, rs9290954,
								rs9837216, rs9872656, rs9834978,
W	3q28	4.17E-09	7			Х	Х	rs9830307

W	KDR	6.46E-24	2	Х	Х	x	х	rs7680198, rs17081840
	MUC7/AMT							rs13105826, rs4694318, rs28751942,
W	Ν	4.27E-08	4	Х			Х	rs28503247
W	BMPR1B-DT	3.88E-10	3			Х	Х	rs11938840, rs6532503, rs7680214
W	5p13.1	2.66E-08	2			Х	Х	rs13165498, rs2220801
W	ARHGAP26	5.06E-10	2			Х	Х	rs7728894, rs1799293
								rs1316379, rs13170063, rs2963462,
W	5q33.3	3.49E-08	6	Х		Х	Х	rs2901003, rs11135035, rs17055653
								rs9371219, rs7740302, rs9371528,
								rs6927162, rs58415480, rs9371246,
W	SYNE1	9.67E-43	7		X	Х	X	rs6557210
			_					rs1812673, rs13231733, rs11976790,
W	6p15.2	4.40E-11	5			X	X	rs1451383, rs1451385
W	HMGN1P19	5.37E-11	2			Х	Х	rs10951860, rs11975261
W	GNRH1	6.06E-12	2			Х	Х	rs7819740, rs13277090
								rs7028213, rs10122243, rs10757288,
			_					rs1333054, rs1537377, rs10965274,
W	CDKN2B-AS1	9.16E-24	9			X	X	rs2779747, rs10738612, rs1095899
W	LCN1P2	4.67E-14	1			Х	Х	rs633862
			_					rs792208, rs792212, rs111958828,
W	RNLS	5.69E-17	6			X	X	rs10788601, rs7922551, rs1935578
		0.005.00	-	v		V	V	rs606651, rs606642, rs476669,
W	ARL14EP-DT	8.96E-33	5	Х		X	X	rs601681, rs76242056
W	PAX6_HS2	1.86E-09	2			X	X	rs6484567, rs2207550
W	FGD6	1.41E-23	2	Х		Х	Х	rs10777675, rs6538622
			_					rs7306496, rs12319554, rs10437892,
W	LINC02456	7.72E-10	5	Х		X	X	rs7296495, rs11111353
147		0.225.10	2			v	v	rs11067288, rs11067298,
W	TBX3-AS1	9.23E-10	3			X	X	rs117549885
W	SRP14-DT	4.16E-09	5	x	х	x	x	rs4924409, rs2412474, rs78053299, rs12441483, rs7162269
W	VAPA	3.56E-08	2	^	^	х Х	X	rs604079, rs486270
W	NFILZ	2.25E-10	1			X	X	rs2967676
VV		2.232-10	1			^	^	rs6075379, rs6081270, rs34478401,
W	DTD1	8.72E-10	4			x	x	rs6045578
W	ZHX3	1.29E-08	3			Х	Х	rs6102464, rs6102467, rs4610114
W	MIRLET7BHG	4.80E-08	3	Х	X		X	rs11702897, rs9626905, rs3859891
Wex	CDC42	4.91E-11	2			Х	X	rs3754496, rs7529389
Wex	RMND1	2.86E-08	3	Х	X	Х	X	rs3778608, rs6913515, rs6904364
								rs13387419, rs77606953,
SCNv2	KCNF1	1.97E-08	5		Х		х	rs10194777, rs2091817, rs1317430
SCNv2	12q24.32	2.64E-08	2		Х			rs10773384, rs10847311

Of the 38 loci with at least one variant in the credible set, 34 were from the W multi-

population meta-analysis, 2 were from Wex, and 2 were from SCN.v2. Fourteen of the credible

sets included variants detectable in part due to new genetic ancestry groups incorporated in the analyses (AMR and AFR). In particular, three loci leveraged the incorporation of all four ancestries to compute the credible set: *FSHR*, *KDR*, and *SRP14-DT*.

176 GWAS Variant Gene Enrichment Analyses

177 From the wide multi-population meta-analysis, we identified 47 unique gene regions 178 that were enriched for significant GWAS variants. Eight genes were specific to the multiancestry W meta-analysis: CDKN2A, CCHCR1, AP3M1, SPECC1, IGF1, DTD1, DNM3, and TCF19. 179 180 Eleven were specific to the EUR meta-analysis: CBX1, GRB14, HOXA5, RPS10, SNX11, CHD6, VIP, 181 LOC105375205, PARPBP, NOL4L, NR2C1, and one (CEBPE) was specific to the AMR meta-182 analysis. Two additional genes were identified for the other phenotypes: TCEA2 with Wex in the 183 multi-ancestry meta-analysis, and HAVCR2 in the PCN.v1 EAS meta-analysis. Full MAGMA results are given in Supplementary Table 5. 184

185 Post-GWAS Multi-Omic Analyses Fuel Pathway Identification

To identify associations between endometriosis and both the transcriptome and proteome, we performed TWAS using uterine tissue eQTL weights from GTEx and PWAS on whole blood pQTLs, inputting the multi-ancestry W GWAS summary statistics (See Methods). The TWAS tested 9,642 genes, and the PWAS tested 300 proteins. There were 11 genes achieving genomewide significance (Bonferroni P value < 0.05) in the TWAS and 1 in the PWAS, shown in Table 3.

191	Table 3: 11 significant TWAS genes and one significant PWAS protein. The p-value thresholds were adjusted for the
192	numbers of tests (TWAS P < 0.05 / 9,642, and PWAS P < 0.05 / 300).

	Z-	Beta	P-
Gene Symbol	score		value
RMND1	8.69	4.92	3.7E-18
		-	
ARL14EP	-8.35	0.16	6.8E-17


		-	
ZBTB2	-6.86	1.77	6.7E-12
VEZT	6.62	0.44	3.5E-11
		-	
KDR	-6.17	0.54	6.7E-10
ARMT1	6.13	0.77	8.9E-10
RP11-		-	
521C20.2	-5.11	0.27	3.3E-07
RP11-		-	
521C20.5	-5.11	0.13	3.3E-07
		-	
CCDC88B	-4.79	0.20	1.7E-06
DTD1	4.77	0.20	1.9E-06
NOL4L	4.57	0.77	4.8E-06
RSPO3	6.08	0.14	1.2E-09

193 Of 11 significant genes identified from TWAS, nine of them were proximal to our 194 significant multi-ancestry W GWAS loci. Three of them are the nearest genes to GWAS loci: 195 ARL14EP, KDR, and DTD1. Three TWAS genes (RMND1, ZBTB2, and ARMT1) are related to the 196 chromosome six cluster of loci which also includes SYNE1 and ESR1. In the GWAS results, RMD1 197 was more prominent in the Wex phenotype. *VEZT* (TWAS P = 3.5E-11) was most significant in 198 the EAS GWAS results and was overlapping with the multi-ancestry GWAS locus FGD6. Two 199 LincRNA genes identified in TWAS, RP11-521C20.2, RP11-521C20.5, are close to the GWAS locus 200 SRP14-DT. The remaining two TWAS genes, NOL4L and CCDC88B, are not proximal to any GWAS 201 loci we identified (at least 20 Mb away). PWAS identified RSPO3 (P = 1.2E-09) as the only 202 significantly-associated protein, which was also a significant locus from our GWAS meta-203 analysis.


204 Identifying Disease-Relevant Cell Types and Crucial Genes

205 We prioritized 18 cell type – menstrual stage pairs with AUROC > 0.6 in which to compare gene

206 expression for the 35 top MAGMA genes in the multi-ancestry W meta-analysis.



207



gene *CD109* was more highly expressed in six: immune myeloid cells, venous cells, glandular
 nuclei, stromal MMP (<u>matrix metallop</u>roteinase – expressing) nuclei, uterine natural killer
 nuclei, and cycling uterine natural killer nuclei.

The expression of *IGF1* was significantly different between cells from endometriosis cases and controls in ten cell type – menstrual stage pairs (three endometrial cell types, two endometrial nucleus types, and all five immune nucleus types). It did not always have the same direction; for seven out of those ten groups, expression of *IGF1* was greater, while for the remaining three (secretory phase ciliated cells, stromal MMP nuclei from donors on hormones, and proliferative phase uterine macrophage nuclei), it was downregulated.

226 WNT4 and ESR1 are well-known endometriosis-associated genes. WNT4's expression 227 was significantly different between endometriosis cases and controls in four cell type -228 menstrual stage pairs. WNT4 expression was higher in both macrophage nucleus populations 229 (eM1 and eM2) in donors taking exogenous hormones and secretory phase perivascular 230 (ePV 2) nuclei. In contrast, WNT4 expression was lower in stromal MMP nuclei from donors on 231 hormones. *ESR1* expression was significantly different in nine cell type – menstrual stage pairs 232 (three secretory, six hormones). All but one association were positive – the one negative T 233 statistic was found in stromal MMP nuclei from donors on hormones. The three secretory 234 groups with ESR1 upregulated in donors with endometriosis were ciliated cells, perivascular 235 (ePV 2) cells, and stromal MMP nuclei.

236 Mergeomics identifies significant biological processes from multi-omic237 integration

Using marker set enrichment analysis (MSEA) on KEGG database gene sets²⁶, we identified one 238 239 significantly enriched pathway that provides insight into the molecular mechanisms underlying 240 endometriosis. The WNT signaling pathway (hsa04310) was the most significantly enriched 241 biological process, driven by markers including RUVBL1, WNT4, and CTBP2 (Supplementary Figure XX). Other significant pathways (FDR P < 0.05) were Focal Adhesion (hsa04510), B cell 242 243 receptor signaling pathway (hsa04662), Notch signaling pathway (hsa04330), and chronic 244 myeloid leukemia (hsa05220). along with pathways in cancer and small cell lung cancer. The 245 detailed module enrichment result is shown in Supplementary Table 6.




Figure 4: Summary of genes identified from multi-omics analysis and their potential role in each of the hallmarks of
 endometriosis.

249 **Discussion**

250 We report the largest multi-population GWAS for endometriosis to date incorporating 251 nearly a million participants from 14 diverse biobanks across the world and increasing the total 252 number of GWAS loci. Although multiple significant loci obtained from our study have been 253 previously implicated in endometriosis pathophysiology, we have identified seven previously 254 unreported GWAS loci and two previously unreported TWAS genes associated with 255 endometriosis, which provides important insights into the underlying genetic architecture of 256 endometriosis across population. We have summarized the major associations based on their 257 involvement in specific biological functions (increased sex steroid hormones, immune 258 regulation, inflammation, cell morphogenesis and vascular development and remodeling) in 259 Figure 4, these could also be defined as five hallmarks of endometriosis.

260 Our ancestry stratified meta-analyses revealed a consistent observed SNP heritability of 261 10-12% for endometriosis for three studied genetic ancestry populations (EUR, EAS, and AFR), 262 which is higher than previously observed SNP heritability of 7% based solely on European 263 populations. The higher and more consistent heritability we observed can be attributed to the 264 unprecedented scale and diversity of our study cohort. The previous GWASs have not included 265 any African-ancestry or Admixed-American-ancestry (AMR) populations, which were essential 266 in the computation of 14 / 38 (37%) credible sets in our fine-mapping analysis. We detected one African-only GWAS locus, POLR2M, and one AMR-only MAGMA gene, CEBPE. By 267

incorporating biobanks from various regions and ancestry backgrounds worldwide, we were
able to capture a more comprehensive genetic landscape of endometriosis.

270 Given that diagnosis codes from the EHR can be unreliable for accurately phenotyping 271 endometriosis, we employed narrow phenotyping algorithms which incorporated procedure 272 codes (surgical and imaging). Despite the diminished sample sizes, there were still genome-273 wide significant loci: one for PCN.v1, two for SCN.v1, and two for SCN.v2. Both GWAS loci for 274 SCN.v2 (KCNF1 and 12q24.32) were successfully fine-mapped, with five and two putative causal 275 variants in their credible sets, respectively. The EAS-only PCN.v1 meta-analysis yielded a 276 significantly enriched gene, HAVCR2, an immune receptor gene near the 5q33.3 GWAS locus, 277 which was not present in the other meta-analyses. Leveraging multi-modal EHR data for more 278 precise phenotyping significantly enhanced our ability to refine and validate genetic 279 associations and uncover deeper biological insights.

Our meta-GWAS and PWAS analyses underscore the potential role of RSPO3 in 280 281 endometriosis pathophysiology. RSPO3, previously known to modulate risk of endometriosis, 282 interacts with WNT4 via Frizzled (FZD) receptors, influencing the WNT/Ca2+ and WNT/ β -catenin 283 pathways^{27,28}. WNT4 interacts with ESR1 (Estrogen Receptor Alpha), key regulator of 284 endometrial cell proliferation and survival throughout the menstrual cycle²⁹. Additionally, 285 scDRS analyses identified ESR1, WNT4, SYNE1, GREB1, IGF1, and FSHB as relevant in 286 endometrial perivascular cells (ePV) from donors in the secretory phase, while RMND1 287 (Required for Meiotic Nuclear Division 1 homolog), ARMT1, and CCDC170 were linked to 288 secretory phase ciliated cells. Collectively, these genes likely promote increased sex steroid hormone production and signaling. This hormonal milieu may, in turn, fuel inflammatory 289

290 responses and dysregulate immune function, potentially driving the progression of 291 endometriosis^{6,30,31}.

Our meta-GWAS and TWAS analyses identified VEZT (Vezatin) and ARL14EP as 292 293 significant. VEZT exhibits menstrual cycle-dependent expression in endometrial glands during 294 the secretory phase and is also relevant in venous cells of individuals on exogenous 295 hormones³². Together with *FGD6*, *VEZT* plays a crucial role in cytoskeletal remodeling. 296 Dysregulation of this process can accelerate cell proliferation, migration, and invasion into the 297 endometrium, promoting the development of ectopic lesions. This dysregulation may also lead 298 to uncontrolled epithelial-mesenchymal transition (EMT), potentially driving endometriosis 299 progression^{32,33}. ARL14EP has previously been linked to depression which is a known endometriosis comorbidity³⁴. It was also prominent in ciliated cells from the secretory phase in 300 301 scDRS analysis. ARL14EP is involved in MHCII movement via the TGF-ß pathway, suggesting a role in immune modulation, a hallmark of endometriosis^{35,36}. Last, we also identified VEGFR2 302 303 (KDR), significant in arterial cells from the secretory phase, and CDKN2A, both known to 304 regulate angiogenesis and endothelial cell adhesion^{37,38}. CDC42, another significant hit, plays a 305 role in vascular remodeling along with *VEGFR2*^{39–41}. Together, these findings highlight pathways 306 in vascular and immune modulation, guiding future functional studies on endometriosis.

Despite the large sample size, heritability observed with GWAS (10-12%) still fails to measure up to the broad sense heritability estimation from a twin study of 47%⁴². Rare variants, structural variants, nonlinear effects, or gene-environment interactions might contribute to endometriosis risk but remain undetected in our analyses. As we leveraged the GWAS results to study other levels of the central dogma, one limitation was that we lacked

312 individual-level transcriptomic/proteomic data. The TWAS and PWAS performance relied on 313 previously-trained *cis*-eQTL expression models, limiting the power, since the models do not 314 capture all the gene expression variability and complex genetic architecture potentially relevant to our phenotype of interest⁴³. Mergeomics assumes that overlapping signals between GWAS, 315 316 TWAS, and PWAS are biologically relevant. The tool primarily considers only the association p-317 value, but not the directionality of association, which may limit the validity of detected 318 biological signals. Additionally, Mergeomics may not fully capture complex interactions between genes or the functional effects of non-coding variants. While this tool does not allow 319 320 us to infer causality, it does generate testable biological hypotheses for further functional 321 assays.

322 In addition to replicating findings from previous studies, we uncovered new insights that 323 advanced our understanding of the genetic underpinnings of endometriosis. Our integrative 324 multi-omics approach, combining genomic data with transcriptomic, proteomic, and single-cell 325 analyses, has provided unprecedented insights into the molecular mechanisms driving this 326 chronic condition. These findings lay a robust foundation for future functional studies to 327 elucidate the precise roles of identified genes and pathways in endometriosis pathogenesis. 328 Moreover, our results have important clinical implications, potentially informing the 329 development of more accurate diagnostic tools, personalized risk prediction models, and 330 targeted therapeutic interventions. As we move forward, this work emphasizes the critical 331 importance of large-scale, diverse genetic studies in unraveling the complexities of 332 multifactorial diseases like endometriosis, paving the way for improved patient outcomes and a deeper understanding of women's health issues globally. 333

334 Methods

335 **Phenotyping**

336 For the EHR-linked biobanks, we used structured data to define the phenotypes. Cases for wide 337 endometriosis (W) were any women with a history of ICD-9, ICD-10, or SNOMED codes for 338 endometriosis. For the wide phenotype excluding adenomyosis (Wex), women with a history of 339 ICD-9, ICD-10, or SNOMED codes for uterine endometriosis were excluded from both cases and 340 controls. Our two narrow case definitions were procedure-confirmed and surgically-confirmed (PCN and SCN). These narrow phenotypes were designed to capture confirmed cases and 341 342 controls of endometriosis based on procedure history including hysterectomies, laparoscopies 343 and ultrasounds. The list of procedure codes (CPT-4 or OPCS) for PCN included all the surgery 344 codes in SCN but added non-obstetric ultrasound codes to account for potential imaging diagnoses. Each of the two narrow phenotypes was tested in two versions: cases versus all 345 346 controls (PCN.v1 and SCN.v1) and cases versus confirmed controls (PCN.v2 and SCN.v2) where 347 confirmed controls were those who had history of the corresponding procedure codes for each 348 phenotype with no history of endometriosis diagnosis. For additional details on the 349 phenotyping algorithms, see Supplemental Appendix 1.

350 Genotyping by Biobank

351 Most contributing biobanks acquired several hundred thousand variants. After those data are 352 collected, then the rest of the genomic variants can be imputed probabilistically based on a 353 reference panel such as TOPMED. Some biobanks used short read whole genome sequencing 354 (WGS) to gather their genomic data. The sequences from the short reads are aligned and

compared to the reference to produce variant calls. References and platform information for
each biobank's genotyping method and QC can be found in Supplemental Appendix 2.

357 Genetic Association Testing

Each contributing biobank performed ancestry-stratified association testing with up to six 358 359 phenotypes (W, Wex, PCN.v1, PCN.v2, SCN.v1, and SCN.v2), depending on whether they had at 360 least 50 cases for that phenotype and ancestry combination. Genetically-informed ancestry 361 (GIA) is defined based on genetic distance from subpopulations of a reference group such as the 1000 Genomes Project dataset⁴⁴ (1KG). Genetic distance is measured using a dimensionality 362 363 reduction technique such as principal component analysis (PCA). Ancestry is then assigned 364 using a classifier such as a mixture model or k-nearest neighbors. For references and methods 365 used for assigning GIA within each biobank, see Supplemental Appendix 3.

366 Contributing biobanks used linear mixed models to estimate the effect of each variant on the six phenotypes. Tools implemented for these tests include $SAIGE^{45}$ and Regenie⁴⁶. 367 368 Association tests were adjusted for principal components, age at EHR data collection, and any 369 biobank-specific batch variables (for example, collection site within eMERGE). For estimation of 370 the null models (SAIGE or Regenie step 1), variants were required to have a call rate of at least 95%, a minor allele frequency of 0.01, and a Hardy-Weinberg p-value of at least 1×10^{-6} . For 371 372 association testing (SAIGE or Regenie step 2), variants were required to have a minor allele 373 count of at least 20, and an imputation quality of at least 0.6. Individuals were included if their 374 overall genotyping rate was at least 95%. A summary of each biobank's exact covariates and QC 375 procedures is in Supplemental Appendix 4.

376 After biobank analyses were completed and collected, summary statistics were cleaned 377 and lifted into genome build hg38 as necessary. Then, inverse variance-weighted, fixed-effect meta-analyses were performed using GWAMA⁴⁷. GWAMA adjusts each study based on its 378 overall genomic inflation factor. Prior to meta-analysis, input summary statistics were restricted 379 380 to variants with a minor allele frequency of at least 0.005 to ensure stability in the estimates. We started by applying the clumping function of Plink 1.9⁴⁸ with the lead SNP p-value threshold 381 set to 5×10^{-8} , the secondary SNP threshold set to 1×10^{-3} , minimum R² of 0.1, and a window of 382 1000kb. 1KG was used as a linkage disequilibrium (LD) reference since the meta-analyses were 383 multi-ancestry. After the variant clumps were identified, any clumps that were physically 384 385 overlapping with one another were merged into loci. Then, we tested if any loci were in LD with $(R^2 > 0.25)$ or proximal to tag SNPs of the 39 autosomal lead SNPs from the 2023 GWAS⁴⁹ to 386 determine whether our hits were known or previously unreported¹⁰. 387

388 Estimation of Observed SNP Heritability

We estimated heritability with the LD-Score Regression tool, LDSC⁵⁰, for four ancestrystratified meta-analyses and the multi-ancestry meta-analysis. LD scores were computed from the full 1KG for the multi-ancestry summary statistics, and from the respective superpopulation subgroups from 1KG for each ancestry-stratified meta-analysis.

393 Variant-Set Enrichment for Identifying Enriched Gene Regions

394 MAGMA⁵¹ was used to assess gene regions within the GWAS results for enrichment. 395 MAGMA uses a model based on multiple regression to test the association of a phenotype with 396 groups of variants. Testing groups of variants increases statistical power over the single-variant

397 GWAS tests performed⁵¹. We utilized gene region definitions from NCBI for human genome 398 build 38, testing about 18,000 genes for each GWAS.

399 Statistical Fine-Mapping for Identification of Putative Causal Variants

MESuSiE⁵² was used to identify causal variants in each significant GWAS locus. We 400 401 extracted the summary statistics from each locus's region in addition to computing LD matrices 402 for that region in all ancestry groups comprising the overall study. For single-ancestry metaanalyses, only one LD matrix was needed, but the loci from the multi-ancestry meta-analyses 403 404 were fine-mapped using LD matrices from AFR, AMR, EAS, and EUR. MESuSiE analyzes whether 405 causal variants are shared between ancestry groups by computing a posterior probability of causality (PIP) for each ancestry alone and for each combination of two or more ancestries. 406 407 SNPs with any PIP value greater than 0.5 are part of the credible set for that locus.

408 Tissue-Specific Transcriptome-Wide Association Study

409 We used GWAS summary statistics from our multi-population W meta-analysis to 410 estimate the association between the variants on expression of genes and the complex trait, 411 endometriosis. We used precomputed eQTL weights from the PredictDB data repository (http://predictdb.org/) which represented *cis*-level associations. The database files comprise of 412 a list of genetic variants (cis-SNPs) used to predict gene expression, located within 1 Mb of a 413 gene, eQTL weights, and covariance information. Those models along with the GWAS summary 414 statistics were input into the summary-based PrediXcan (S-PrediXcan) pipeline for the 415 416 transcriptome-wide association study (TWAS), scanning for genes whose expression levels were associated with endometriosis⁵³. We used Bonferroni P < 0.05 (corrected for 9,642 tests) to 417 identify statistically significant TWAS genes. 418

419 Proteome-Wide Association Study

420 We performed a proteome-wide association study (PWAS) to investigate the association between genetically predicted protein levels and endometriosis. We used summary-level GWAS 421 data from the multi-ancestry W meta-analysis, and pQTL models developed by Schubert et al^{54} . 422 423 The models were derived from SOMAscan assay of plasma proteins measured in multi-ethnic Trans-omics for Precision Medicine (TOPMed) Multi-omics pilot study, capturing 1mb cis-424 regulatory window. We used baseline models only, essentially those models were trained under 425 426 standard conditions without any additional adjustments for other covariates or interaction 427 terms, typically a reference model for general prediction of gene expression based solely on 428 genetic variation. Only models with a predictive correlation (rho) of at least 0.1 and a z-score p-429 value threshold of 0.05, meaning that the association between the SNPs and gene expression is 430 statistically significant, were included. The PWAS was thereby performed on 309 most robust. 431 and reliable models for the analysis. We employed the S-PrediXcan pipeline to perform the PWAS. We used Bonferroni-correct P value threshold (P < 0.05 / 309) for identifying significant 432 PWAS genes. 433

434 Integration with Single-Cell Data

Single cell data are rich resources for understanding the biology of diseases. A recentlypublished endometrial single cell atlas includes gene expression data for cells, nuclei, immune cells, and immune nuclei, covering over 40 different cell types, three menstrual phases, and four different endometrial pathologies⁵⁵. We leveraged these data to compute single-cell disease-relevance scores (scDRSs) based on the associated genes from the GWAS, as computed by MAGMA. Disease risk scores were computed and normalized using the scDRS software⁵⁶. We

removed any cell types labeled as "hormones," as the authors did in the atlas release paperwhen they performed fGWAS.

For each cell type and menstrual phase, we compared the scDRSs of cells from donors 443 444 with and without endometriosis. We performed one-sided t-tests to compare the distributions, hypothesizing that the scDRSs of cells from endometriosis cases should be higher than that of 445 446 cells from endometriosis controls. We also computed the area under the receiver-operating 447 curve (AUROC) to see how well the scDRS distinguished between endometriosis case and 448 control donors. From there, we prioritized cell type – menstrual phase combinations with significant t-tests and AUROC > 0.6 for further examination. We compared the expression of the 449 450 top MAGMA genes between case and control donors using t-tests to identify which genes were driving the performance of the scDRS. 451

452 Merge-Omics

Using the GWAS, TWAS, and PWAS results, we conducted a marker set enrichment analysis (MSEA) with Mergeomics²⁴. MSEA identifies key marker sets (genes or proteins) significantly enriched for associations across multi-omics data. The markers were mapped to Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways using gene annotations. We used GWAS, TWAS and PWAS markers (rsIDs for GWAS and gene names for TWAS and PWAS), along with their corresponding –log10 transformed p-values as input for the tool. We enriched for KEGG pathways with FDR < 0.05.

460 **Acknowledgments**

Research reported in this publication was supported by the Eunice Kennedy Shriver National
Institute of Child Health and Human Development of the National Institutes of Health under
award number R01HD110567.

We acknowledge the Penn Medicine BioBank (PMBB) for providing data and thank the patientparticipants of Penn Medicine who consented to participate in this research program. We would also like to thank the Penn Medicine BioBank team and Regeneron Genetics Center for providing genetic variant data for analysis. The PMBB is approved under IRB protocol# 813913 and supported by Perelman School of Medicine at University of Pennsylvania, a gift from the Smilow family, and the National Center for Advancing Translational Sciences of the National Institutes of Health under CTSA award number UL1TR001878.

This phase of the eMERGE Network was initiated and funded by the NHGRI through the 471 472 following grants: U01HG008657 (Group Health Cooperative/University of Washington); U01HG008685 (Brigham and Women's Hospital); U01HG008672 (Vanderbilt University Medical 473 474 Center); U01HG008666 (Cincinnati Children's Hospital Medical Center); U01HG006379 (Mayo Clinic); U01HG008679 (Geisinger Clinic); U01HG008680 (Columbia University Health Sciences); 475 476 U01HG008684 (Children's Hospital of Philadelphia); U01HG008673 (Northwestern University); 477 U01HG008701 (Vanderbilt University Medical Center serving as the Coordinating Center); U01HG008676 (Partners Healthcare/Broad Institute); and U01HG008664 (Baylor College of 478 479 Medicine).

We gratefully acknowledge All of Us participants for their contributions, without whom this research would not have been possible. We also thank the National Institutes of Health's All of Us Research Program for making available the participant data examined in this study.

483 This research has been conducted using the Taiwan Biobank Resource. We thank all the participants and investigators of the Taiwan Biobank. We thank the National Center for 484 485 Genome Medicine, Academia Sinica, Taiwan, for the technical support in the genotyping. 486 We thank National Core Facility for Biopharmaceuticals (NCFB, 112-2740-B-492-001) and 487 National Center for High-performance Computing (NCHC) of National Applied Research 488 Laboratories (NARLabs) of Taiwan for providing computational resources and storage 489 resources. This study was supported by the National Health Research Institutes (NP-109, 110, 111, 112, 113-PP-09), Ministry of Science and Technology (MOST 109-2314-B-400-017, 110-490 491 2314-B-400-028-MY3), and National Science and Technology Council (NSCT 113-2628-B-400-492 002), Taiwan.

493 The Trøndelag Health Study (The HUNT Study) is a collaboration between HUNT Research Centre (Faculty of Medicine and Health Sciences, NTNU, Norwegian University of Science and 494 495 Technology), Trøndelag County Council, Central Norway Regional Health Authority, and the 496 Norwegian Institute of Public Health. The genotyping in HUNT was financed by the National 497 Institutes of Health; University of Michigan; the Research Council of Norway; the Liaison 498 Committee for Education, Research and Innovation in Central Norway; and the Joint Research 499 Committee between St Olavs hospital and the Faculty of Medicine and Health Sciences, NTNU. 500 The genetic investigations of the HUNT Study are a collaboration between researchers from the HUNT Center for Molecular and Clinical Epidemiology (formerly known as the K.G. Jebsen 501

502 Center for Genetic Epidemiology as of August 1st 2023), NTNU, and the University of Michigan 503 Medical School and the University of Michigan School of Public Health. We thank HUNT 504 participants for donating their time, samples, and information to help others; clinicians and 505 other employees at Nord-Trøndelag Hospital Trust for their support and for contributing to data 506 collection.

507 **References**

- 508 1. Christ, J. P. et al. Incidence, prevalence, and trends in endometriosis diagnosis: a United
- 509 States population-based study from 2006 to 2015. American Journal of Obstetrics and
- 510 *Gynecology* **225**, 500.e1-500.e9 (2021).
- 511 2. Agarwal, S. K. *et al.* Clinical diagnosis of endometriosis: a call to action. *American Journal of*512 *Obstetrics and Gynecology* 220, 354.e1-354.e12 (2019).
- 513 3. Fauconnier, A. & Chapron, C. Endometriosis and pelvic pain: epidemiological evidence of 514 the relationship and implications. *Human Reproduction Update* **11**, 595–606 (2005).
- 515 4. Coccia, M. E., Nardone, L. & Rizzello, F. Endometriosis and Infertility: A Long-Life Approach
- to Preserve Reproductive Integrity. International Journal of Environmental Research and
 Public Health 19, 6162 (2022).
- 518 5. Fatumo, S. *et al.* A roadmap to increase diversity in genomic studies. *Nat Med* 28, 243–250
 519 (2022).
- 520 6. Sapkota, Y. et al. Meta-analysis identifies five novel loci associated with endometriosis
- 521 highlighting key genes involved in hormone metabolism. *Nat Commun* **8**, 15539 (2017).

- 522 7. Rahmioglu, N. *et al.* The genetic basis of endometriosis and comorbidity with other pain and
 523 inflammatory conditions. *Nat Genet* 55, 423–436 (2023).
- 524 8. Verma, A. et al. The Penn Medicine BioBank: Towards a Genomics-Enabled Learning
- 525 Healthcare System to Accelerate Precision Medicine in a Diverse Population. *Journal of*
- 526 *Personalized Medicine* **12**, 1974 (2022).
- 527 9. Genomic data in the All of Us Research Program. *Nature* **627**, 340–346 (2024).
- 528 10. Verma, A. et al. Diversity and Scale: Genetic Architecture of 2,068 Traits in the VA Million

 529
 Veteran
 Program.
 2023.06.28.23291975
 Preprint
 at

 530
 https://doi.org/10.1101/2023.06.28.23291975 (2023).
 6.2023.06.28.23291975 (2023).
 6.2023.06.28.23291975 (2023).

- 531 11. Zhou, W. *et al.* Global Biobank Meta-analysis Initiative: Powering genetic discovery across
 532 human disease. *Cell Genomics* 2, 100192 (2022).
- 12. Nagai, A. *et al.* Overview of the BioBank Japan Project: Study design and profile. *Journal of Epidemiology* 27, S2–S8 (2017).
- 535 13. Pulley, J., Clayton, E., Bernard, G. R., Roden, D. M. & Masys, D. R. Principles of human
 536 subjects protections applied in an opt-out, de-identified biobank. *Clin Transl Sci* 3, 42–48
 537 (2010).
- 538 14. Roden, D. *et al.* Development of a Large-Scale De-Identified DNA Biobank to Enable
 539 Personalized Medicine. *Clinical Pharmacology & Therapeutics* 84, 362–369 (2008).
- 540 15. Wiley, L. K. et al. Building a vertically integrated genomic learning health system: The
- 541 biobank at the Colorado Center for Personalized Medicine. *The American Journal of Human*
- 542 *Genetics* **111**, 11–23 (2024).

- 543 16. Gottesman, O. et al. The Electronic Medical Records and Genomics (eMERGE) Network:
- 544 past, present, and future. *Genet Med* **15**, 761–771 (2013).
- 545 17. David, S. P. et al. Personalized medicine in a community health system: the NorthShore
- 546 experience. *Front. Genet.* **14**, (2023).
- 547 18. Brumpton, B. M. *et al.* The HUNT study: A population-based cohort for genetic research.
- 548 *Cell Genomics* **2**, (2022).
- 549 19. Rovite, V. et al. Genome Database of the Latvian Population (LGDB): Design, Goals, and
- 550 Primary Results. *Journal of Epidemiology* **28**, 353–360 (2018).
- 551 20. Boutin, N. T. *et al.* The Evolution of a Large Biobank at Mass General Brigham. *Journal of*
- 552 *Personalized Medicine* **12**, 1323 (2022).
- 553 21. Fan, C.-T., Lin, J.-C. & Lee, C.-H. Taiwan Biobank: A Project Aiming to Aid Taiwan's Transition
 554 into a Biomedical Island. *Pharmacogenomics* 9, 235–246 (2008).
- 555 22. Bycroft, C. *et al.* The UK Biobank resource with deep phenotyping and genomic data. *Nature*556 562, 203–209 (2018).
- 557 23. Katon, J. G., Plowden, T. C. & Marsh, E. E. Racial disparities in uterine fibroids and
- endometriosis: a systematic review and application of social, structural, and political
 context. *Fertility and Sterility* **119**, 355–363 (2023).
- 560 24. Ding, J. *et al.* Mergeomics 2.0: a web server for multi-omics data integration to elucidate
- 561 disease networks and predict therapeutics. *Nucleic Acids Research* **49**, W375–W387 (2021).
- 562 25. Kurki, M. I. et al. FinnGen provides genetic insights from a well-phenotyped isolated
- 563 population. *Nature* **613**, 508–518 (2023).

- 564 26. Kanehisa, M. & Goto, S. KEGG: Kyoto Encyclopedia of Genes and Genomes. *Nucleic Acids*565 *Research* 28, 27–30 (2000).
- 566 27. Tao, T., Mo, X. & Zhao, L. Identifying novel potential drug targets for endometriosis via
 567 plasma proteome screening. *Front. Endocrinol.* 15, (2024).
- 568 28. Scholz, B. et al. Endothelial RSPO3 Controls Vascular Stability and Pruning through Non-
- 569 canonical WNT/Ca2+/NFAT Signaling. *Developmental Cell* **36**, 79–93 (2016).
- 570 29. Gallagher, C. S. et al. Genome-wide association and epidemiological analyses reveal
- 571 common genetic origins between uterine leiomyomata and endometriosis. *Nat Commun*
- **10**, 4857 (2019).
- 573 30. Marla, S. et al. Genetic risk factors for endometriosis near estrogen receptor 1 and
- 574 coexpression of genes in this region in endometrium. *Molecular Human Reproduction* 27,
 575 gaaa082 (2021).
- 576 31. García-Gómez, E. et al. Regulation of Inflammation Pathways and Inflammasome by Sex
- 577 Steroid Hormones in Endometriosis. *Front. Endocrinol.* **10**, (2020).
- 578 32. Holdsworth-Carson, S. J. *et al.* Endometrial vezatin and its association with endometriosis
 579 risk. *Human Reproduction* **31**, 999–1013 (2016).
- 33. Szymański, M. *et al.* Role of Cyclins and Cytoskeletal Proteins in Endometriosis: Insights into
 Pathophysiology. *Cancers* 16, 836 (2024).
- 582 34. Adewuyi, E. O. *et al.* Genetic analysis of endometriosis and depression identifies shared loci
- and implicates causal links with gastric mucosa abnormality. *Hum Genet* 140, 529–552
 (2021).

- 585 35. Paul, P. et al. A Genome-wide Multidimensional RNAi Screen Reveals Pathways Controlling
- 586 MHC Class II Antigen Presentation. *Cell* **145**, 268–283 (2011).
- 587 36. Hogg, C. *et al.* Macrophages inhibit and enhance endometriosis depending on their origin.
- 588 *Proceedings of the National Academy of Sciences* **118**, e2013776118 (2021).
- 589 37. Jin, Y. et al. Deletion of Cdc42 Enhances ADAM17-Mediated Vascular Endothelial Growth
- 590 Factor Receptor 2 Shedding and Impairs Vascular Endothelial Cell Survival and 591 Vasculogenesis. *Molecular and Cellular Biology* **33**, 4181–4197 (2013).
- 592 38. Barry, D. M. et al. Cdc42 is required for cytoskeletal support of endothelial cell adhesion
- 593 during blood vessel formation in mice. *Development* **142**, 3058–3070 (2015).
- 594 39. Sugino, N., Kashida, S., Karube-Harada, A., Takiguchi, S. & Kato, H. Expression of vascular
- endothelial growth factor (VEGF) and its receptors in human endometrium throughout the
 menstrual cycle and in early pregnancy. (2002) doi:10.1530/rep.0.1230379.
- 597 40. Cerione, R. A. Cdc42: new roads to travel. *Trends in Cell Biology* **14**, 127–132 (2004).
- 598 41. Slack, M. A. & Gordon, S. M. Protease Activity in Vascular Disease. *Arterioscler Thromb Vasc*
- 599 Biol **39**, e210–e218 (2019).
- 42. Saha, R. *et al.* Heritability of endometriosis. *Fertility and Sterility* **104**, 947–952 (2015).
- 43. Mai, J., Lu, M., Gao, Q., Zeng, J. & Xiao, J. Transcriptome-wide association studies: recent
- advances in methods, applications and available databases. *Commun Biol* **6**, 1–10 (2023).
- 44. An integrated map of genetic variation from 1,092 human genomes. *Nature* 491, 56–65
 (2012).
- 45. Zhou, W. et al. Efficiently controlling for case-control imbalance and sample relatedness in
- 606 large-scale genetic association studies. *Nat Genet* **50**, 1335–1341 (2018).

- 607 46. Mbatchou, J. *et al.* Computationally efficient whole-genome regression for quantitative and
- 608 binary traits. *Nat Genet* **53**, 1097–1103 (2021).
- 609 47. Mägi, R. & Morris, A. P. GWAMA: software for genome-wide association meta-analysis.
- 610 *BMC Bioinformatics* **11**, 288 (2010).
- 611 48. Purcell, S. et al. PLINK: A Tool Set for Whole-Genome Association and Population-Based
- 612 Linkage Analyses. *Am J Hum Genet* **81**, 559–575 (2007).
- 49. Rahmioglu, N. et al. The genetic basis of endometriosis and comorbidity with other pain and
- 614 inflammatory conditions. *Nat Genet* **55**, 423–436 (2023).
- 615 50. LD Score regression distinguishes confounding from polygenicity in genome-wide
- association studies | Nature Genetics. https://www.nature.com/articles/ng.3211.
- 51. Leeuw, C. A. de, Mooij, J. M., Heskes, T. & Posthuma, D. MAGMA: Generalized Gene-Set
 Analysis of GWAS Data. *PLOS Computational Biology* **11**, e1004219 (2015).
- 619 52. Gao, B. & Zhou, X. MESuSiE enables scalable and powerful multi-ancestry fine-mapping of
- 620 causal variants in genome-wide association studies. *Nat Genet* **56**, 170–179 (2024).
- 621 53. Gamazon, E. R. *et al.* A gene-based association method for mapping traits using reference
- 622 transcriptome data. *Nat Genet* **47**, 1091–1098 (2015).
- 54. Schubert, R. *et al.* Protein prediction for trait mapping in diverse populations. *PLOS ONE* 17,
 e0264341 (2022).
- 55. Marečková, M. *et al.* An integrated single-cell reference atlas of the human endometrium. *Nat Genet* 56, 1925–1937 (2024).
- 627 56. Zhang, M. J. *et al.* Polygenic enrichment distinguishes disease associations of individual cells
- 628 in single-cell RNA-seq data. *Nat Genet* 54, 1572–1580 (2022).

629